Navigation Links
Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Date:4/11/2011

he 100 mg IR topiramate administered twice daily.  USL255 also showed a lower maximum plasma concentration than IR topiramate.  

USL255 is the subject of a global Phase III clinical trial (PREVAIL), being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), as well as an open-label extension study.

Upsher-Smith's Expanding CNS Pipeline

USL255 is the lead investigational drug in Upsher-Smith's expanding central nervous system (CNS) development pipeline, with an anticipated indication for the adjunctive treatment of adult epilepsy patients with partial onset seizures (POS).  USL's pipeline includes a number of other investigational drug programs.  Another program in this pipeline, USL261 (nasal midazolam), is under development for the management of cluster seizures in epilepsy.  Other programs include USL260 (tonabersat), an investigational drug and first-in-class neuronal gap junction modulator for the potential treatment of epilepsy.  Upsher-Smith has previously announced its partnership with Proximagen Group Plc for the PRX1 program for the symptomatic treatment of Parkinson's disease, in which Upsher-Smith is responsible for the world-wide development and commercialization of PRX1 under the direction of a joint steering committee on which there is representation of both Upsher-Smith and Proximagen.

About Epilepsy and Parkinson's Disease

Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions.  Almost three million people in the U.S. have some form of epilepsy with about 200,000 new cases of epilepsy diagnosed each year.(1)

Parkinson's disease is a chronic, progressive neurodegenerative disease that causes impairment in motor function, as well as many non-motor complications throughout the various stages of the disease.  As many as one million people in the Uni
'/>"/>

SOURCE Upsher-Smith Laboratories
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
2. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
5. Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
6. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
9. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
10. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
11. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  Armada Health ... of the new Armada corporate website ( www.armadahealthcare.com ... communicate Armada,s unique and first-to-market services and its ... focused on the specialty pharmacy industry. ... of the Armada business model in delivering an ...
(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
... EORTC 40983 (EPOC),Intergroup Study Results, CHICAGO, June ... phase III EORTC 40983 Intergroup study, or ... peri-operative (pre and post,surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin ... for colon cancer,5-fluorouracil/leucovorin (5-FU/LV)) given to patients ...
... Phase II Study Results Presented at Society ... 04, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... with the radioisotope,iodine-131, was found to be ...
Cached Medicine Technology:The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:5/21/2013)... (PRWEB) May 21, 2013 HealthSmart continues ... expanding national presence has required the hiring of new ... HealthSmart is pleased to announce that Dawn Powell has ... serving as the Director of Account Management in the ... offices in Irving, Texas. With extensive client management, employee ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... Phoseon Technology will present their advanced ... Annual IMI European Ink Jet Conference (June 5-6, ... continues to invest in product development to enable breakthrough ... LED curing in printing applications. Phoseon currently has ... offering both air cooled and water cooled solutions to ...
(Date:5/21/2013)... Modern couples have countless strains on ... Sexuality and Relationship Workshops, couples are learning the ... habits for their relationship. There are both private ... individuals at Texas Counseling. Their goal is to ... to develop long term solutions. , Developing ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
Breaking Medicine News(10 mins):Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2
... CORVALLIS, Ore. Researchers have developed a type of wearable, ... heart rate and respiration at the same time it records ... diagnostics and patient care. The device is just two ... contact with the skin and can operate for a week ...
... magnetic resonance equipment available, researchers at the University of ... structure of biological molecules -- potentially leading to new ... cancer and Alzheimer,s disease. The findings appear in ... and Journal of Biological Chemistry "These ...
... -- About one million packets of birth control pills are ... of a packaging error that could reduce the effectiveness of ... 14 lots of Lo/Ovral-28 tablets and 14 lots of generic ... Pfizer discovered that some blister packs may contain either too ...
... Kathleen Doheny HealthDay Reporter , WEDNESDAY, Feb. 1 ... pauses in breathing during sleep, is already known to boost ... apnea to so-called silent strokes, in which there is tissue ... study, researchers found that rapid memory loss before a stroke ...
... (HealthDay News) -- Many adults whose parents suffered a stroke ... middle age that may precede a stroke, a new study ... age of 61 who underwent MRI brain scans to assess ... white matter lesions and other signs of aging or damage ...
... multiforme (GBM) is the most common of all malignant ... GBM have a poor prognosis because it is a ... to current therapies. New therapeutic approaches are therefore much ... University of California, San Francisco, have now identified a ...
Cached Medicine News:Health News:Protein structures give disease clues 2Health News:Pfizer Recalls 1 Million Packets of Birth Control Pills 2Health News:Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds 2Health News:Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds 3Health News:Adult Children of Stroke Sufferers May Show Signs of Brain Aging, Too 2
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
... offers a display, ramp capabilities ... also has features that make ... session meter records the number ... than four hours - giving ...
... CPAP System is the smallest and lightest ... the market. It is designed to help ... while complying with therapy. The GoodKnight 420S ... date/time usage data. It also detects persistent ...
Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....
Medicine Products: